Alios BioPharma has signed an exclusive worldwide licensing agreement with Versitech to develop, manufacture and market medication to combat influenza viruses.
In addition, the companies have also entered into two other influenza-related, non-exclusive licence agreements and a sponsored research agreement.
Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.
Alios BioPharma president and CEO Lawrence Blatt said that the compounds and technology derived from the deal will provide key therapeutic options to help improve patients infected from influenza virus.
See Also:
